Cisapride treatment of constipation in parkinson's disease
Cisapride treatment of constipation in parkinson's disease
复制标题
西沙必利治疗帕金森病便秘
DOI：
10.1002/mds.870080315
复制
发表时间：
1993
影响因子：
8.6
通讯作者：
K. Schimrigk
中科院分区：
文献类型：
--
作者：
W. Jost;K. Schimrigk
痉挛是帕金森病（PD）的常见症状，可能是由自主神经系统，特别是肌间神经丛的变性引起的。西沙必利是一种能增加肌间神经丛乙酰胆碱释放的药物。在一项初步研究中，西沙必利治疗在20名PD患者中进行了研究，其中10名女性和10名男性患有延迟肠道传输。在所有病例中，西沙必利治疗与结肠传输显著加速相关，如通过射线照片上观察到的不透射线颗粒所测量的。颗粒计数从治疗前的平均53.8下降到西沙必利治疗后的30.4。未观察到不良反应和“过冲效应”，如腹泻。我们的研究结果表明，西沙必利可能会减轻与帕金森病相关的便秘。
Constipation, a frequent symptom in Parkinson's disease (PD), is probably caused by degeneration of the autonomic nervous system, particularly the myenteric plexus. Cisapride is a drug that causes increased release of acetylcholine in the myenteric plexus. In a pilot study, cisapride therapy was investigated in 20 PD patients, 10 women and 10 men, who suffered from delayed intestinal transit. In all cases, cisapride therapy was associated with a significant acceleration of colonic transit, as measured by radioopaque pellets viewed on radiographs. Pellet count fell from a mean of 53.8 pretreatment to 30.4 after cisapride treatment. No adverse reaction and no “overshoot effects,” such as diarrhea, were seen. Our findings suggest that cisapride may alleviate the constipation associated with Parkinson's disease.